Teste de toxicidade de lidocaína e indometacina e suas respectivas nanoformulações em diferentes vias em embrião de galinha

Abstract

For the safe marketing and use of drugs, it is essential to know their therapeutic window and especially their toxicity. Aiming at efficiency, timeliness, metabolism, rapid physiological development, less stress to the animal and less ethical bureaucracy, the use of chicken embryos (CE) as a research alternative is justified. The objective of this study was to evaluate whether CE can be a model for toxicity tests with drugs and their nanoformulations and the interference of the inoculation route on the results. For this study, 572 CE were used with 11 days of incubation. Four inoculation routes were tested, these being the Shell Membrane (SM), Chorioallantoic Membrane (CAM), Amnio (AM) and Allantois (ALA) and the toxicity of four drugs was analyzed, commercial lidocaine (CL), indomethacin (CI) and its nanoformulations (NL and NI respectively). Were used 5 different dilutions per drug and for each dilution six CE were used. The eggs were artificially incubated and observed daily to assess mortality and embryodiagnosis of CEs that died within 16 days of incubation. Overall, considering all doses, the mortality rate of commercial Lidocaine was similar to that of nanoformulated Lidocaine, while the mortality of nanoformulated Indomethacin was higher than that of commercial Indomethacin via the AM and CAM pathways. The use of chicken embryos suggested a practical, accessible and efficient model, essential for obtaining results showing that nanoformulated lidocaine had a similar mortality rate to conventional lidocaine, while nanoformulated indomethacin demonstrated a higher mortality rate compared to commercial indomethacin.